Navigation Links
Antibiotic-resistant strain of E. coli increasing among older adults and residents of nursing homes
Date:3/12/2013

Antibiotic-resistant Escherichia coli (E. coli) continues to proliferate, driven largely by expansion of a strain of E. coli know as sequence type ST131. A new study points to hospitals and long-term care facilities (LTCF) as settings in which this antibiotic-resistant strain is increasingly found. The study is published in the April issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

E. coli is the most common gram-negative pathogen, causing both gastrointestinal disease and extraintestinal infections such as pneumonia, meningitis, and bloodstream, urinary tract, abdominal, and wound infections. Strains of E. coli that are resistant to single or multiple classes of antibiotics are becoming more prevalent. E. coli ST131 is commonly associated with fluoroquinolone resistance.

"The expansion of E. coli strain ST131 is recognized as a pandemic, but has received comparatively little attention in the United States," said Ritu Banerjee, lead investigator of the study. "Alarmingly, the pace of new antibiotic development has not kept up with the emergence of antibiotic-resistant E. coli, making development of strategies to halt further emergence and spread of these strains a public health priority."

In this retrospective study, investigators evaluated nearly 300 consecutive patients in Olmsted County, Minnesota with extraintestinal E. coli infections and found ST131 to be a dominant, antimicrobial-resistant clonal group associated with older age, long-term care facility residence, complicated infections, history of urinary tract infection, and prior antimicrobial use.

LTCF residence was the strongest predictor of ST131 infection, with LTCF residents having 8 times the risk of contracting E. coli ST131 compared with non-LTCF residents. This trend coincides with the increasing prevalence of ST131 among patients 65 years and older. It is likely that extensive antibiotic exposure, close contact with other antibiotic-exposed individuals, age and health-associated alterations in intestinal microbiota all contribute to the high prevalence of ST131 among the elderly population.

Patients with ST131 isolates were often treated with ineffective antibiotics at first and as a result they had recurrent or persistent symptoms. In the cohort, ST131 isolates were also more than twice as likely to be healthcare-associated infections as compared to community-associated infections.

"The finding that clonal expansion of ST131 is occurring primarily in healthcare and long-term care facilities indicates an urgent need for improved antibiotic use and infection control practices within such institutions, both to reduce selection for ST131 and to block further transmission. Efforts that focus on reducing overuse and misuse of fluoroquinolones are likely to have the greatest impact on ST131 prevalence, given the strong association between ST131 and fluoroquinolone resistance," said Banerjee.


'/>"/>

Contact: Kate Enos
kenos@gymr.com
202-745-5071
Society for Healthcare Epidemiology of America
Source:Eurekalert

Related medicine news :

1. Strains of antibiotic-resistant Staph bacteria show seasonal preference; Children at higher risk in summer
2. Synthetic corkscrew peptide kills antibiotic-resistant Gram-negative bacteria
3. Antibiotic-Resistant Gonorrhea Spreading: WHO
4. Prediction of seasonal flu strains improves chances of universal vaccine
5. With Acne, Bacteria Strain on Your Skin May Be Culprit
6. Some Whooping Cough Strains Now Outsmarting Vaccine
7. CDC Researchers Spot Increase in New Stomach Bug Strain
8. Hog Ties, Duct Tape, and Airlines: Lawyers at Console & Hollawell Discuss Liability Concerns over Restraining Passengers Mid-Flight
9. Scientists Shed Light on Fungus Behind Deadly Pneumonia Strain
10. Infection With 2 HIV Strains Slows Disease Progression
11. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: